We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+30.25%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$12B
AUM Growth
+$2.23B
Cap. Flow
-$2.3B
Cap. Flow %
-19.15%
Top 10 Hldgs %
76.74%
Holding
140
New
18
Increased
23
Reduced
51
Closed
10

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$121M
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$106M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$76.4M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$51.5M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$34.6M

Top Sells

Rank Stock Value
1
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$653M
2
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$73M
3
VNDA icon
Vanda Pharmaceuticals
VNDA
+$30.8M
4
PCYC
PHARMACYCLICS INC
PCYC
+$17.3M
5
XOMA
Xoma
XOMA
+$8.13M

Sector Composition

Rank Sector Weight
1 Healthcare 45.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LPCN icon
76
Lipocine
LPCN
$17.2M
$3.38M 0.03%
28,775
-637
-2% -$69.3K
NDRM
77
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$3.35M 0.03%
250,000
– –
ASMB icon
78
Assembly Biosciences
ASMB
$700M
$3.31M 0.03%
+20,833
New +$2.82M
BLPH
79
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$3.21M 0.03%
+23,333
New +$3.63M
ABUS icon
80
Arbutus Biopharma
ABUS
$1.03B
$3.15M 0.03%
180,582
-303,574
-63% -$6.22M
ZGNX
81
DELISTED
Zogenix, Inc.
ZGNX
$3.15M 0.03%
287,308
-6,492
-2% -$73.5K
AUPH icon
82
Aurinia Pharmaceuticals
AUPH
$2.22B
$3.12M 0.03%
711,499
-16,170
-2% -$64.1K
IRWD icon
83
Ironwood Pharmaceuticals
IRWD
$709M
$2.71M 0.02%
201,981
-211,334
-51% -$2.77M
BDSI
84
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$2.69M 0.02%
255,866
+45,845
+22% +$626K
AFMD
85
DELISTED
Affimed
AFMD
$2.52M 0.02%
40,000
– –
ASPX
86
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
$2.51M 0.02%
+25,000
New +$1.67M
ITCI
87
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.49M 0.02%
+104,166
New +$2.33M
ENTA icon
88
Enanta Pharmaceuticals
ENTA
$392M
$2.31M 0.02%
75,357
– –
SVRA icon
89
Savara
SVRA
$1.15B
$2.28M 0.02%
67,249
-957
-1% -$33.3K
VTAE
90
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$2.2M 0.02%
+187,597
New +$2.53M
ACHN
91
DELISTED
Achillion Pharmaceuticals
ACHN
$2.11M 0.02%
214,237
-224,100
-51% -$2.8M
PTN
92
Palatin Technologies
PTN
$17.2M
$2.09M 0.02%
1,640
– –
TCRT icon
93
Alaunos Therapeutics
TCRT
$4.47M
$2.04M 0.02%
1,262
-29
-2% -$43K
TARA icon
94
Protara Therapeutics
TARA
$228M
$2.01M 0.02%
4,323
– –
VXRT
95
DELISTED
Vaxart
VXRT
$1.99M 0.02%
78,471
-22,157
-22% -$610K
MRNS
96
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.8M 0.02%
50,000
-1,119
-2% -$49.1K
ASND icon
97
Ascendis Pharma A/S
ASND
$16.6B
$1.74M 0.01%
+100,000
New +$1.82M
CLLS
98
Cellectis
CLLS
$342M
$1.73M 0.01%
+50,000
New +$1.81M
ISEE
99
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.66M 0.01%
35,649
-1,127
-3% -$58.5K
MDWD icon
100
MediWound
MDWD
$171M
$1.63M 0.01%
32,143
– –
2 3
4
5 6

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q1 2015 Portfolio in Review

As of Q1 2015, Julian Baker held 140 positions worth $12B, up 23% from $9.8B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Julian Baker withdrew a net $2.3B in Q1 2015, closing 10 positions and reducing 51 holdings. Its most notable exit was AVANIR PHARMACEUTICALS, INC CL A, an estimated $653M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 47% a quarter earlier.

Against the trend, Julian Baker opened a new position in Invitae Corporation worth $110M.

  • Julian Baker's largest Q1 2015 buy was Invitae Corporation: 6,554,967 shares worth $110M.
  • Julian Baker added most to SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q1 2015, an estimated $106M increase.
  • Julian Baker's biggest Q1 2015 reduction was Vanda Pharmaceuticals, cutting an estimated $30.8M.
  • Julian Baker fully exited AVANIR PHARMACEUTICALS, INC CL A in Q1 2015, selling an estimated $653M.
  • Julian Baker's ten largest holdings make up 77% of its $12B portfolio in Q1 2015.
  • Julian Baker opened 18 new positions and closed 10 in Q1 2015.
  • Julian Baker's portfolio value rose 23% quarter-over-quarter to $12B.

Based on Baker Bros. Advisors's 13F filing for Q1 2015, filed 15 May 2015.